mk-3207
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00548353)
Timeline
Indications
Studied for
Mechanism of action
CALCRL antagonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CN1C(=O)C2(CCCC2)NC[C@H]1c1cc(F)cc(F)c1)Nc1ccc2c(c1)C[C@@]1(C2)C(=O)Nc2ncccc21- Mol. weight
- 557.6 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1910936 ↗
Also known as
- 2-(8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro(4.5)dec-9-yl)-n-(2'-oxo-1,1',2',3-tetrahydrospiro(indene-2,3'-pyrrolo(2,3-b)pyridin)-5-yl)acetamide
- mk3207
- mk3207
- mk3207
- mk3207
- mk 3207
- mk-3207
- mk-3207
- mk-3207
- mk-3207
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00712725 | Phase 2 | Jul 1, 2008 | Merck |
| NCT00548353 | Phase 1 | Aug 1, 2007 | Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 2 | 2 | 2007 |
1 organizations
Page 1 / 1